Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 849

1.

Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.

Loeb S, Zhu X, Schroder FH, Roobol MJ.

BJU Int. 2012 Dec;110(11):1678-83. doi: 10.1111/j.1464-410X.2012.11367.x. Epub 2012 Sep 21.

2.

Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.

Steuber T, Budäus L, Walz J, Zorn KC, Schlomm T, Chun F, Ahyai S, Fisch M, Sauter G, Huland H, Graefen M, Haese A.

BJU Int. 2011 Jun;107(11):1755-61. doi: 10.1111/j.1464-410X.2010.09730.x. Epub 2010 Oct 13.

3.

Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.

Lughezzani G, Gallina A, Larcher A, Briganti A, Capitanio U, Suardi N, Lista G, Abrate A, Sangalli MN, Buffi N, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

BJU Int. 2013 May;111(5):723-30. doi: 10.1111/j.1464-410X.2012.11114.x. Epub 2012 Apr 4.

4.

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x. Epub 2010 Sep 30.

5.

Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.

Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, Schröder FH, Roobol MJ.

BJU Int. 2012 Dec;110(11):1672-7. doi: 10.1111/j.1464-410X.2012.11434.x. Epub 2012 Aug 29.

6.

20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer.

Mitchell CR, Boorjian SA, Umbreit EC, Rangel LJ, Carlson RE, Karnes RJ.

BJU Int. 2012 Dec;110(11):1709-13. doi: 10.1111/j.1464-410X.2012.11372.x. Epub 2012 Aug 30.

7.

Outcomes in patients with Gleason score 8-10 prostate cancer: relation to preoperative PSA level.

McGuire BB, Helfand BT, Loeb S, Hu Q, O'Brien D, Cooper P, Yang X, Catalona WJ.

BJU Int. 2012 Jun;109(12):1764-9. doi: 10.1111/j.1464-410X.2011.10628.x. Epub 2011 Oct 21.

8.

Intermediate term biochemical progression rates after radical prostatectomy and radiotherapy in patients with screen detected prostate cancer.

Krygiel JM, Smith DS, Homan SM, Sumner W 2nd, Nease RF Jr, Brownson RC, Catalona WJ.

J Urol. 2005 Jul;174(1):126-30.

PMID:
15947596
9.

Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era.

Isbarn H, Wanner M, Salomon G, Steuber T, Schlomm T, Köllermann J, Sauter G, Haese A, Heinzer H, Huland H, Graefen M.

BJU Int. 2010 Jul;106(1):37-43. doi: 10.1111/j.1464-410X.2009.09134.x. Epub 2009 Dec 11.

10.

Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years.

Sooriakumaran P, Haendler L, Nyberg T, Gronberg H, Nilsson A, Carlsson S, Hosseini A, Adding C, Jonsson M, Ploumidis A, Egevad L, Steineck G, Wiklund P.

Eur Urol. 2012 Nov;62(5):768-74. doi: 10.1016/j.eururo.2012.05.024. Epub 2012 May 18.

PMID:
22633365
11.

Impact of surgical margin status on prostate-cancer-specific mortality.

Chalfin HJ, Dinizo M, Trock BJ, Feng Z, Partin AW, Walsh PC, Humphreys E, Han M.

BJU Int. 2012 Dec;110(11):1684-9. doi: 10.1111/j.1464-410X.2012.11371.x. Epub 2012 Jul 12.

12.
13.
14.

Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management.

Nguyen PL, Chen MH, Catalona WJ, Alexander BM, Roehl KA, Loeb S, D'Amico AV.

Cancer. 2008 Dec 1;113(11):3146-52. doi: 10.1002/cncr.23926.

15.

Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?

van den Bergh RC, Steyerberg EW, Khatami A, Aus G, Pihl CG, Wolters T, van Leeuwen PJ, Roobol MJ, Schröder FH, Hugosson J; Swedish and Dutch sections of the European Randomized Study of Screening for Prostate Cancer..

Cancer. 2010 Mar 1;116(5):1281-90. doi: 10.1002/cncr.24882.

16.

Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.

Bokhorst LP, Zhu X, Bul M, Bangma CH, Schröder FH, Roobol MJ.

BJU Int. 2012 Dec;110(11):1654-60. doi: 10.1111/j.1464-410X.2012.11481.x. Epub 2012 Oct 8.

17.
18.
19.

Radical prostatectomy in very high-risk localized prostate cancer: long-term outcomes and outcome predictors.

Joniau S, Hsu CY, Gontero P, Spahn M, Van Poppel H.

Scand J Urol Nephrol. 2012 Jun;46(3):164-71. doi: 10.3109/00365599.2011.637956. Epub 2012 Feb 27.

PMID:
22364377
20.

Long-term cancer control after radical prostatectomy and bilateral pelvic lymph node dissection for pT3bN0M0 prostate cancer in the prostate-specific antigen era.

Fairey AS, Daneshmand S, Skinner EC, Schuckman A, Cai J, Lieskovsky G.

Urol Oncol. 2014 Feb;32(2):85-91. doi: 10.1016/j.urolonc.2013.03.005. Epub 2013 Oct 30.

PMID:
24183191

Supplemental Content

Support Center